KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Equity: 2014-2025

Historic Return on Equity for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to -0.54%.

  • Xenon Pharmaceuticals' Return on Equity fell 28.00% to -0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.54%, marking a year-over-year decrease of 28.00%. This contributed to the annual value of -0.29% for FY2024, which is 7.00% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Return on Equity is -0.54%, which was down 22.89% from -0.44% recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Return on Equity high stood at -0.14% for Q2 2022, and its period low was -0.54% during Q3 2025.
  • In the last 3 years, Xenon Pharmaceuticals' Return on Equity had a median value of -0.26% in 2024 and averaged -0.30%.
  • Its Return on Equity has fluctuated over the past 5 years, first grew by 11bps in 2022, then decreased by 28bps in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Return on Equity (Quarterly) stood at -0.20% in 2021, then climbed by 3bps to -0.17% in 2022, then decreased by 6bps to -0.23% in 2023, then dropped by 9bps to -0.32% in 2024, then dropped by 28bps to -0.54% in 2025.
  • Its last three reported values are -0.54% in Q3 2025, -0.44% for Q2 2025, and -0.36% during Q1 2025.